Tigatuzumab: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
nothing is "recent" in Wikipedia. this is a primary source, and this was WP:REFSPAM
Ekdowling (talk | contribs)
13 edits
No edit summary
Line 42: Line 42:
'''Tigatuzumab''' ('''CS-1008''') is a [[monoclonal antibodies|monoclonal antibody]]<ref>[http://www.who.int/medicines/services/inn/RL60prepublication.pdf WHO Drug Information]</ref> for the treatment of cancer. {{as of|2009|10}}, a [[clinical trial]] for the treatment of [[pancreatic cancer]] has been completed,<ref>[[National Cancer Institute|NCI]]: [http://www.cancernet.gov/ncicancerbulletin/042109/page3 Combination Therapy Targets Pancreatic Cancer Stem Cells]</ref> Phase II trials for [[colorectal cancer]]<ref>NCI: [http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=654374&version=HealthProfessional&protocolsearchid=6875774 CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin]</ref> and non-small cell [[lung cancer]]<ref>NCI: [http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=657101&version=HealthProfessional&protocolsearchid=6875774 CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)]</ref> are running, and a study for [[ovarian cancer]] has been approved.<ref>NCI: [http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=650804&version=HealthProfessional&protocolsearchid=6875774 Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer]</ref>
'''Tigatuzumab''' ('''CS-1008''') is a [[monoclonal antibodies|monoclonal antibody]]<ref>[http://www.who.int/medicines/services/inn/RL60prepublication.pdf WHO Drug Information]</ref> for the treatment of cancer. {{as of|2009|10}}, a [[clinical trial]] for the treatment of [[pancreatic cancer]] has been completed,<ref>[[National Cancer Institute|NCI]]: [http://www.cancernet.gov/ncicancerbulletin/042109/page3 Combination Therapy Targets Pancreatic Cancer Stem Cells]</ref> Phase II trials for [[colorectal cancer]]<ref>NCI: [http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=654374&version=HealthProfessional&protocolsearchid=6875774 CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin]</ref> and non-small cell [[lung cancer]]<ref>NCI: [http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=657101&version=HealthProfessional&protocolsearchid=6875774 CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)]</ref> are running, and a study for [[ovarian cancer]] has been approved.<ref>NCI: [http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=650804&version=HealthProfessional&protocolsearchid=6875774 Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer]</ref>


The drug targets [[TNFRSF10B|member 10b of the tumor necrosis factor receptor superfamily]] (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein overexpressed in many kinds of tumour.<ref>NCI: [http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=489323 CS-1008]</ref>
The drug targets [[TNFRSF10B|member 10b of the tumor necrosis factor receptor superfamily]] (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein with limited expression in normal tissues but overexpressed in many kinds of tumours, including colon, gastric, pancreatic, lung, and cervical.<ref>NCI: [http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=489323 CS-1008]</ref><ref>{{cite journal |vauthors= Ciprotti M, et al. |date= August 2015 |title= phase I imaging and pharmacodynamic trial of CS-1008 in patients with metastatic colorectal cancer |url= http://ascopubs.org/doi/full/10.1200/JCO.2014.60.4256 |journal= Journal of Clinical Oncology |volume= 33 |issue= 24 |pages= 2609-16 |doi= 10.1200/JCO.2014.60.4256}}</ref>

In 2015, a Phase I study was performed to investigate how [[biodistribution]], quantitative tumor uptake, and antitumor response in patients with metastatic [[colorectal cancer]] was impacted by CS-1008. Researchers tracked these objectives through use of trace-labeling and [[SPECT]] imaging over the course of patients’ treatment and found heterogeneity of tigatuzumab uptake in tumors, that tigatuzumab uptake is not dose dependent (though higher doses are tolerated with minimal toxicity), and that tigatuzumab uptake is predictive of clinical benefit in the treatment of metastatic colorectal cancer.<ref>{{cite journal |vauthors= Ciprotti M, et al. |date= August 2015 |title= phase I imaging and pharmacodynamic trial of CS-1008 in patients with metastatic colorectal cancer |url= http://ascopubs.org/doi/full/10.1200/JCO.2014.60.4256 |journal= Journal of Clinical Oncology |volume= 33 |issue= 24 |pages= 2609-16 |doi= 10.1200/JCO.2014.60.4256}}</ref>



== References ==
== References ==

Revision as of 02:25, 21 April 2018

Tigatuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetTNFRSF10B (TRAIL-R2)
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6406H9924N1716O2012S46
Molar mass144.6 kg/mol g·mol−1
 ☒NcheckY (what is this?)  (verify)

Tigatuzumab (CS-1008) is a monoclonal antibody[1] for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer has been completed,[2] Phase II trials for colorectal cancer[3] and non-small cell lung cancer[4] are running, and a study for ovarian cancer has been approved.[5]

The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein with limited expression in normal tissues but overexpressed in many kinds of tumours, including colon, gastric, pancreatic, lung, and cervical.[6][7]

In 2015, a Phase I study was performed to investigate how biodistribution, quantitative tumor uptake, and antitumor response in patients with metastatic colorectal cancer was impacted by CS-1008. Researchers tracked these objectives through use of trace-labeling and SPECT imaging over the course of patients’ treatment and found heterogeneity of tigatuzumab uptake in tumors, that tigatuzumab uptake is not dose dependent (though higher doses are tolerated with minimal toxicity), and that tigatuzumab uptake is predictive of clinical benefit in the treatment of metastatic colorectal cancer.[8]


References

  1. ^ WHO Drug Information
  2. ^ NCI: Combination Therapy Targets Pancreatic Cancer Stem Cells
  3. ^ NCI: CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
  4. ^ NCI: CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
  5. ^ NCI: Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
  6. ^ NCI: CS-1008
  7. ^ Ciprotti M, et al. (August 2015). "phase I imaging and pharmacodynamic trial of CS-1008 in patients with metastatic colorectal cancer". Journal of Clinical Oncology. 33 (24): 2609–16. doi:10.1200/JCO.2014.60.4256.
  8. ^ Ciprotti M, et al. (August 2015). "phase I imaging and pharmacodynamic trial of CS-1008 in patients with metastatic colorectal cancer". Journal of Clinical Oncology. 33 (24): 2609–16. doi:10.1200/JCO.2014.60.4256.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tigatuzumab&oldid=837476699"